Show simple item record

dc.contributor.authorMukasa, Kiguli James
dc.contributor.authorHerbert, Itabangi
dc.contributor.authorDaniel, Atwine
dc.contributor.authorSserunkuma, Kibuka Livingstone
dc.contributor.authorJoel, Bazira
dc.contributor.authorFrederick, Byarugaba
dc.date.accessioned2022-01-14T09:46:57Z
dc.date.available2022-01-14T09:46:57Z
dc.date.issued2015
dc.identifier.citationMukasa, K. J., Herbert, I., Daniel, A., Sserunkuma, K. L., Joel, B., & Frederick, B. (2015). Antifungal susceptibility patterns of vulvovaginal Candida species among women attending antenatal clinic at Mbarara Regional Referral Hospital, South Western Uganda. British microbiology research journal, 5(4), 322.en_US
dc.identifier.urihttp://ir.must.ac.ug/xmlui/handle/123456789/1184
dc.description.abstractAims—To identify the Candida species that cause vulvovaginal candidiasis and determine their antifungal susceptibility patterns. Study Design—This was a cross-sectional study. Place and Duration of Study—The study was conducted at the antenatal clinic of Mbarara Regional Referral Hospital in Mbarara Municipality, between December 2012 and February 2013. Methods—High vaginal swabs from 456 pregnant women were subjected to microscopy and culture on Sabouraud Dextrose Agar. Candida isolates were identified by the germ tube and Analytical profile index (API® Candida) tests. Susceptibility to fluconazole, itraconazole and voriconazole was determined by the Etest strips and for clotrimazole and nystatin by the disc diffusion method on Mueller Hinton agar supplemented with 2%w/v glucose and 0.5μg/ml methylene blue dye. Results—Of the 456 High vaginal swabs cultured, 207 grew Candida species. Species distribution was as follows: C. albicans (78.95%), C. glabrata (14.35%), C. krusei (3.35%), C. tropicalis (1.44%), C. famata (0.96%), C. parapsilosis (0.48%) and C. lusitaniae (0.48%). Resistance to nystatin was only observed in 0.61% of C.albicans. Resistance to clotrimazole was observed in 50%, 36.67% and 0.61% of C. famata, C. glabrata and C. albicans respectively. C. krusei showed a high resistance of 71.43% to fluconazole. C. glabrata, C. krusei, C. famata and C. lusitaniae exhibited 100% resistance to itraconazole. Resistance to voriconazole of less than 11% was exhibited by only C. albicans and C. glabrata. Conclusion—C.albicans was susceptible to most antifungal agents tested except itraconazole and voriconazole. All isolates were susceptible to nystatin except less than 1% of Candida albicans. Non-albicans demonstrated resistance to some drugs especially itraconazole. We recommend use of Nystatin for empirical management of vulvovaginal candidiasis among pregnant women.en_US
dc.description.sponsorshipMEPI-MESAU Grant Number 5R24TW008886 supported by OGAC, NIH and HRSA.en_US
dc.language.isoen_USen_US
dc.publisherBritish microbiology research journalen_US
dc.subjectAntifungalen_US
dc.subjectSusceptibleen_US
dc.subjectResistanten_US
dc.subjectVulvovaginal candidiasisen_US
dc.subjectCandida speciesen_US
dc.titleAntifungal Susceptibility Patterns of Vulvovaginal Candida species among Women Attending Antenatal Clinic at Mbarara Regional Referral Hospital, South Western Ugandaen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record